Blandine Guffroy

Strasbourg, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.

Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.

Journal: Bone marrow transplantation

Published: March 09, 2026

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

Journal: American journal of hematology

Published: February 06, 2026

Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.

Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.

Journal: Blood advances

Published: April 16, 2025

Renin-Angiotensin System Drives Leukemia Progression by Reprogramming the Niche.

Renin-Angiotensin System Drives Leukemia Progression by Reprogramming the Niche.

Journal: Discovery medicine

Published: February 20, 2025

Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study.

Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study.

Journal: Blood advances

Published: September 19, 2024

CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy.

CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy.

Journal: Joint bone spine

Published: December 11, 2023

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.

Journal: Haematologica

Published: December 07, 2023

CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.

CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.

Journal: American journal of hematology

Published: November 27, 2023

Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).

Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).

Journal: Blood advances

Published: September 19, 2023

Unusual presentation of toxoplasmosis with gastro-intestinal involvement in HLA non-identical stem cell transplantation.

Unusual presentation of toxoplasmosis with gastro-intestinal involvement in HLA non-identical stem cell transplantation.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: January 21, 2021

Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study.

Factors associated with coinfections in invasive aspergillosis: a retrospective cohort study.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: October 21, 2020

CDX2 regulates ACE expression in blood development and leukemia cells.

CDX2 regulates ACE expression in blood development and leukemia cells.

Journal: Blood advances

Published: October 07, 2020

Showing 1-12 of 23

Last Updated: 09/26/2026